Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Vainchenker

Showing results (11-20 of 266) with videos related to

Pageof 27
Sort By:
Blood|October 7, 2021
The megakaryocyte: a cell with 3 faces as a mythic god?William Vainchenker, Hana Raslova
Blood|August 7, 2025
CD24 senescent neutrophils as key players in myelofibrosisWilliam Vainchenker, Nasrine Yahmi
Blood|June 13, 2024
DNMT3A gates IFN-induced MPN HSC exhaustionStefan N Constantinescu, William Vainchenker
Hematology. American Society of Hematology. Education Program|December 13, 2012
Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?Stefan N Constantinescu, William Vainchenker
Blood|August 28, 2020
Megakaryocytes tame erythropoiesis with TGFβ1Jean-Luc Villeval, William Vainchenker
Hematology. American Society of Hematology. Education Program|November 24, 2005
A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseasesWilliam Vainchenker, Stefan N Constantinescu
Best Practice & Research. Clinical Haematology|June 20, 2006
Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse modelsHedia Chagraoui, Françoise Wendling, William Vainchenker
Methods in Molecular Biology (Clifton, N.J.)|July 1, 2004
Isolation and culture of megakaryocyte precursorsNajet Debili, Fawzia Louache, William Vainchenker
Medecine Sciences : M/S|June 30, 2005
[A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera]Valérie Ugo, Chloé James, William Vainchenker
Haematologica|December 2, 2016
Eltrombopag, a potent stimulator of megakaryopoiesisHana Raslova, William Vainchenker, Isabelle Plo
Pageof 27

Showing results (11-20 of 266) with videos related to

Sort By:
Pageof 27
Blood|October 7, 2021
The megakaryocyte: a cell with 3 faces as a mythic god?William Vainchenker, Hana Raslova
Blood|August 7, 2025
CD24 senescent neutrophils as key players in myelofibrosisWilliam Vainchenker, Nasrine Yahmi
Blood|June 13, 2024
DNMT3A gates IFN-induced MPN HSC exhaustionStefan N Constantinescu, William Vainchenker
Hematology. American Society of Hematology. Education Program|December 13, 2012
Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?Stefan N Constantinescu, William Vainchenker
Blood|August 28, 2020
Megakaryocytes tame erythropoiesis with TGFβ1Jean-Luc Villeval, William Vainchenker
Hematology. American Society of Hematology. Education Program|November 24, 2005
A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseasesWilliam Vainchenker, Stefan N Constantinescu
Best Practice & Research. Clinical Haematology|June 20, 2006
Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse modelsHedia Chagraoui, Françoise Wendling, William Vainchenker
Methods in Molecular Biology (Clifton, N.J.)|July 1, 2004
Isolation and culture of megakaryocyte precursorsNajet Debili, Fawzia Louache, William Vainchenker
Medecine Sciences : M/S|June 30, 2005
[A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera]Valérie Ugo, Chloé James, William Vainchenker
Haematologica|December 2, 2016
Eltrombopag, a potent stimulator of megakaryopoiesisHana Raslova, William Vainchenker, Isabelle Plo
Pageof 27